Genmab A-S
![Genmab A-S](https://api.admiralmarkets.com/trade_icons/bright-128/GMAB.png)
Closed
1,865.5 0.24
Overview
Share price change
24h
Min
1863
Max
1873
Income | 83M 1.4B |
---|---|
Sales | 1.3B 5.4B |
P/E Sector Avg | 21.02 103.001 |
EPS | 21.7 |
Profit margin | 26.074 |
EBITDA | 423M 2.1B |
Recommendations | Neutral |
---|---|
12 Months Forecast | -1.49 downside |
Market Cap | -261M 122B |
---|---|
Previous open | 1865.26 |
Previous close | 1865.5 |
Genmab A-S Chart
Related News
Genmab A-S Forecast
Price Target
By TipRanks
-1.49% downside
12 Months Forecast
Average 2,493.35 DKK -1.49%
High 3,320 DKK
Low 308.417 DKK
Based on 7 Wall Street analysts offering 12 month price targets forGenmab A-S - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Genmab A-S
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.